<DOC>
	<DOCNO>NCT00216255</DOCNO>
	<brief_summary>The objective study determine effect pagoclone symptom Persistent Developmental Stuttering , use flexible dose titration regimen persistent developmental stuttering patient 18 65 year age .</brief_summary>
	<brief_title>EXPRESS : Examining Pagoclone Persistent Developmental Stuttering Study</brief_title>
	<detailed_description />
	<mesh_term>Stuttering</mesh_term>
	<criteria>PDS define DSMIVTR criterion , symptom start age 8 , total overall score 1836 SSI3 Englishspeaking , 8th grade education , able understand cooperate study requirement without assistance Not pregnant breastfeed Able consent No diagnose CNS/Mental health disorder last 6 month No use psychotropic medication medication stutter within 4 week prior screen No use nonmedicinal stuttering treatment 5 month prior study No use illicit drug opiates kind</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Persistent Developmental Stuttering</keyword>
</DOC>